text size: T | T
Back to Snapshot
Company Description

Contact Info

1 North Waukegan Road

North Chicago, IL 60064

United States

Phone: 847-932-7900


AbbVie Inc. operates as a research-based biopharmaceutical company worldwide. The company develops and markets advanced therapies that address various complex and serious diseases. The company’s products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company also has a pipeline of promising new medicines, including approximately 50 compounds or indications in clinical development across such important medical specialties as immunology, virology/liver disease, oncology, neurological diseases and women's health. In 2015, the company completed its acquisition of Pharmacyclics, Inc., a biopharmaceutical company that develops and commercializes novel therapies for people impacted by cancer, and its primary asset IMBRUVICA, a highly effective treatment for hematologic malignancies. Products The company’s portfolio of products include a line of therapies that address various complex and serious diseases. HUMIRA HUMIRA (adalimumab) is a biologic therapy administered as a subcutaneous injection. It is approved to treat various autoimmune diseases in the United States, Canada, and Mexico (collectively, North America), and in the European Union: HUMIRA is also approved in approximately 60 other markets, including Japan, China, Brazil, and Australia. HUMIRA was introduced to the market in January 2003. HUMIRA is the company’s major product. The United States composition of matter (compound) patent covering adalimumab (which is sold under the trademark HUMIRA) is expected to expire in December 2016, and the equivalent European Union patent is expected to expire in the majority of European Union countries in October 2018. In addition, in the United States, non-composition of matter patents covering adalimumab expire no earlier than 2022. The company continues to dedicate research and development efforts to expanding indications for HUMIRA, including in the fields of rheumatology, gastroenterology (pediatric ulcerative colitis), and ophthalmology (uveitis). A regulatory application for uveitis has been filed in the United States. The company continues to work on HUMIRA formulation and delivery improvements to improve convenience and the overall patient experience. IMBRUVICA IMBRUVICA (ibrutinib) is an oral, once-daily therapy that inhibits a protein called Bruton's tyrosine kinase (BTK). IMBRUVICA is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received approximately one prior therapy, CLL patients who have del 17p and patients with Waldenström's macroglobulinemia. IMBRUVICA is also approved for the treatment of patients with mantle cell lymphoma (MCL) who have received approximately one prior therapy. IMBRUVICA is one of the first medicines to receive a U.S. Food and Drug Administration (FDA) approval after being granted a Breakthrough Therapy Designation and IMBRUVICA is one of the few therapies to receive three separate designations. HCV Products VIEKIRA PAK (ombitsavir, paritaprevir, and ritonavir tablets; dasabuvir tablets) is an all-oral, short-course, interferon-free therapy, with or without ribavirin, for the treatment of adult patients with genotype 1 chronic HCV, including those with compensated cirrhosis. VIEKIRA PAK was approved by the FDA in 2014. In Europe, the company’s HCV treatment is marketed as VIEKIRAX + EXVIERA and is approved for use in patients with genotype 1 and genotype 4 HCV. The European Commission granted marketing authorization for this treatment in January 2015. In July 2015, the FDA approved the company’s TECHNIVIE (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of adults with genotype 4 HCV infection in the United States. Additional Virology Products The company’s additional virology


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

ABBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ABBV.
View Industry Companies

Industry Analysis


Industry Average

Valuation ABBV Industry Range
Price/Earnings 17.6x
Price/Sales 4.0x
Price/Book 17.6x
Price/Cash Flow 17.4x
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ABBVIE INC, please visit www.abbvie.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.